OBJECTIVE To explore the clinical characteristics of patients with COVID-19-associated pulmonary as-pergillosis(CAPA)among those with acute respiratory distress syndrome(ARDS)and to analyze the risk factors for CAPA.METHODS A total of 117 patients with ARDS admitted to Peking University People's Hospital from Dec.1,2022 to Jan.31,2023 were selected.Based on the diagnostic criteria for CAPA,patients were divided into the CAPA group(n=13)and the non-CAPA group(n=104).Clinical characteristics of CAPA patients were ana-lyzed,and risk factors were summarized by multivariate logistic regression analysis.RESULTS Compared with non-CAPA patients,a high proportion of CAPA paitents had a low oxygenation index at admission(＜200 mmHg:61.54％vs.39.42％),those required more invasive respiratory support(ventilator and EC MO:38.46％vs.5.77％),and had a glucocorticoid treatment duration＞10 days(76.92％vs.16.35％).CAPA pa-tients also received more treatments such as tocilizumab(38.46％vs.11.54％)and antiviral drugs(92.31％vs.50.00％),had longer hospital stays(24.00 vs.16.00 days)and a higher in-hospital mortality rate(69.23％vs.21.15％).The use of invasive mechanical ventilation/ECMO during hospitalization(OR=11.386,P=0.013)and therapeutic doses of glucocorticoids for＞10 days(OR=15.671,P＜0.001)were risk factors for CAPA in patients with ARDS.CONCLUSIONS Among COVID-19 patients with ARDS,CAPA patients receive more thera-peutic drugs and treatments during hospitalization.CAPA is associated with the use of invasive mechanical ventila-tion or ECMO and prolonged use of therapeutic doses of glucocorticoids during hospitalization.

OBJECTIVE To explore the clinical characteristics of patients with COVID-19-associated pulmonary as-pergillosis(CAPA)among those with acute respiratory distress syndrome(ARDS)and to analyze the risk factors for CAPA.METHODS A total of 117 patients with ARDS admitted to Peking University People's Hospital from Dec.1,2022 to Jan.31,2023 were selected.Based on the diagnostic criteria for CAPA,patients were divided into the CAPA group(n=13)and the non-CAPA group(n=104).Clinical characteristics of CAPA patients were ana-lyzed,and risk factors were summarized by multivariate logistic regression analysis.RESULTS Compared with non-CAPA patients,a high proportion of CAPA paitents had a low oxygenation index at admission(＜200 mmHg:61.54％vs.39.42％),those required more invasive respiratory support(ventilator and EC MO:38.46％vs.5.77％),and had a glucocorticoid treatment duration＞10 days(76.92％vs.16.35％).CAPA pa-tients also received more treatments such as tocilizumab(38.46％vs.11.54％)and antiviral drugs(92.31％vs.50.00％),had longer hospital stays(24.00 vs.16.00 days)and a higher in-hospital mortality rate(69.23％vs.21.15％).The use of invasive mechanical ventilation/ECMO during hospitalization(OR=11.386,P=0.013)and therapeutic doses of glucocorticoids for＞10 days(OR=15.671,P＜0.001)were risk factors for CAPA in patients with ARDS.CONCLUSIONS Among COVID-19 patients with ARDS,CAPA patients receive more thera-peutic drugs and treatments during hospitalization.CAPA is associated with the use of invasive mechanical ventila-tion or ECMO and prolonged use of therapeutic doses of glucocorticoids during hospitalization.

An 86-year-old female patient with pulmonary infection was treated with IV infusions of ceftriaxone sodium 2. 0 g once daily,azithromycin 0. 5 g once daily,and ambroxol hydrochloride 30 mg twice daily. About 30 minutes after the fourth infusion of azithromycin,the patient abruptly developed chest tightness and suffocation. Electrocardiography showed Ⅲ degree atrioventricular block. Azithromycin was stopped immediately and she was treated with oxygen inhalation. One hour later,the symptoms of chest tightness and suffocation disappeared. Five hours later,a repeat electrocardiography showed sinus rhythm. Azithromycin was not given again and the similar symptoms did not recur any more.

An 86-year-old female patient with pulmonary infection was treated with IV infusions of ceftriaxone sodium 2. 0 g once daily,azithromycin 0. 5 g once daily,and ambroxol hydrochloride 30 mg twice daily. About 30 minutes after the fourth infusion of azithromycin,the patient abruptly developed chest tightness and suffocation. Electrocardiography showed Ⅲ degree atrioventricular block. Azithromycin was stopped immediately and she was treated with oxygen inhalation. One hour later,the symptoms of chest tightness and suffocation disappeared. Five hours later,a repeat electrocardiography showed sinus rhythm. Azithromycin was not given again and the similar symptoms did not recur any more.